Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 36

The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.

Exploiting phage-antibiotic synergies to disrupt Pseudomonas aeruginosa PAO1 biofilms in the context of orthopedic infections

De Soir, Steven, Parée, Hortence, Kamarudin, Nur Hidayatul Nazirah, Wagemans, Jeroen, Lavigne, Rob, Braem, Annabel, Merabishvili, Maya, De Vos, Daniel, Pirnay, Jean-Paul, Van Bambeke, Françoise·2024·Microbiology Spectrum

Abstract

In recent years, bacteriophages (or phages) have reentered the spotlight as alternative or adjuvant therapeutic agents to antibiotics. Their efficacy in more recalcitrant forms of infections like biofilms, frequently encountered in the orthopedic setting, remains less characterized. The present study aimed at evaluating the activity of phage-antibiotic combinations against Pseudomonas aeruginosa biofilms. A large collection of phages was de novo isolated from a wide variety of environmental sources. Three phages with a large host range against a.o. clinical orthopedic isolates, PSP2 ( Yuavirus ), PSP3 ( Pbunavirus ), and PSP30 ( Bruynoghevirus ), were selected for phage-antibiotic synergy assays on mature P. aeruginosa PAO1 biofilms. Phages were combined with ciprofloxacin, meropenem, and ceftazidime, all used as standard of care in bone-related infections. Significant reductions in both cell counts and biomass were observed for all phage-antibiotic combinations. The highest reduction in viable cell counts was observed for PSP3 and PSP2 in combination with ceftazidime [4.58 and 4.30 log 10 Colony Forming Units (CFU)/well], followed by all phage combinations with ciprofloxacin (up to 3.56 log 10 CFU/well). The highest reduction in biomass was obtained by combining PSP3 with ciprofloxacin (29.8%). Metabolic assays confirmed these findings with reductions in biofilm respiratory rate of up to 65%. Scanning electron microscopy imaging of PAO1 biofilms grown on titanium coupons and treated by ciprofloxacin and PSP30 confirmed the efficacy of the combined treatment with PSP30 and ciprofloxacin. This study highlights the synergetic effects of phage-antibiotic combinations on P. aeruginosa biofilms, thereby offering a promising approach to combat biofilm-associated infections. IMPORTANCE: Biofilm-related infections are among the most difficult-to-treat infections in all fields of medicine due to their antibiotic tolerance and persistent character. In the field of orthopedics, these biofilms often lead to therapeutic failure of medical implantable devices and urgently need novel treatment strategies. This forthcoming article aims to explore the dynamic interplay between newly isolated bacteriophages and routinely used antibiotics and clearly indicates synergetic patterns when used as a dual treatment modality. Biofilms were drastically more reduced when both active agents were combined, thereby providing additional evidence that phage-antibiotic combinations lead to synergism and could potentially improve clinical outcome for affected patients.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1128/spectrum.03219-23

Cites

2 of 2 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 2 references

Research works printed but not linked: 90

  1. 10.3390/v10020064 · DOI · Paper page
  2. 10.1007/s00284-016-1166-x · DOI · Paper page
  3. 10.3390/antibiotics9110795 · DOI
  4. 10.1038/nrmicro.2016.94 · DOI · Paper page
  5. 10.1128/JB.182.10.2675-2679.2000 · DOI · Paper page
  6. 10.1002/jor.24019 · DOI
  7. 10.1016/j.heliyon.2018.e01067 · DOI · Paper page
  8. 10.1016/j.cmi.2014.10.024 · DOI · Paper page
  9. 10.1086/668421 · DOI
  10. 10.1302/2058-5241.4.180092 · DOI
  11. 10.7759/cureus.15634 · DOI
  12. 10.23750/abm.v88i2-S.6518 · doi:10.23750/abm.v88i2-s.6518
  13. 10.1007/s11914-019-00548-4 · DOI · Paper page
  14. 10.3389/fmed.2020.513242 · doi:10.3389/fmed.2020.513242
  15. 10.1093/ofid/ofad051 · doi:10.1093/ofid/ofad051
  16. 10.1016/j.copbio.2021.02.002 · DOI
  17. 10.1371/journal.pone.0007740 · DOI · Paper page
  18. 10.1007/s00253-017-8224-6 · DOI · Paper page
  19. 10.1021/acsptsci.0c00045 · DOI
  20. 10.3390/v13101965 · DOI
  21. 10.3390/v11100891 · DOI · Paper page
  22. 10.3390/antibiotics8030103 · DOI · Paper page
  23. 10.1208/s12248-019-0315-0 · DOI
  24. 10.1007/s12250-019-00192-3 · DOI
  25. 10.3389/fmicb.2015.01315 · DOI
  26. 10.3390/v10080438 · DOI
  27. 10.3390/antibiotics11070839 · DOI
  28. 10.2147/NSA.S325594 · DOI
  29. 10.3390/antibiotics12030497 · DOI
  30. 10.1186/s12864-017-3729-z · DOI
  31. 10.1089/phage.2020.0015 · doi:10.1089/phage.2020.0015
  32. 10.1371/journal.pone.0000799 · DOI
  33. 10.1002/em.22267 · DOI · Paper page
  34. 10.3855/jidc.12094 · DOI
  35. 10.1128/AEM.02850-14 · DOI · Paper page
  36. 10.1128/AAC.00900-21 · doi:10.1128/aac.00900-21
  37. 10.1007/s10068-016-0153-0 · doi:10.1007/s10068-016-0153-0
  38. 10.1007/s10068-016-0192-6 · DOI
  39. 10.1128/AAC.00461-20 · doi:10.1128/aac.00461-20
  40. 10.3390/antibiotics10020174 · DOI
  41. 10.3390/v13101898 · DOI
  42. 10.1089/mdr.2021.0324 · DOI
  43. 10.3390/antibiotics10070849 · DOI
  44. 10.3390/antibiotics9110749 · doi:10.3390/antibiotics9110749
  45. 10.3389/fmicb.2018.00127 · DOI
  46. 10.1139/cjm-2022-0080 · DOI
  47. 10.1128/spectrum.00096-22 · DOI
  48. 10.1016/j.ebiom.2022.104045 · DOI · Paper page
  49. 10.3390/microorganisms7110556 · doi:10.3390/microorganisms7110556
  50. 10.3390/v11100954 · DOI
  51. 10.1128/AAC.00993-20 · DOI
  52. 10.3390/antibiotics11091175 · DOI
  53. 10.3390/antibiotics11030392 · DOI
  54. 10.1007/s00705-018-3811-0 · doi:10.1007/s00705-018-3811-0
  55. 10.1128/AEM.02085-18 · doi:10.1128/aem.02085-18
  56. 10.1016/j.ijpharm.2018.09.024 · DOI
  57. 10.3389/fcimb.2019.00022 · DOI · Paper page
  58. 10.3390/microorganisms9010152 · DOI
  59. 10.3390/ph14030184 · DOI
  60. 10.3390/antibiotics10080946 · doi:10.3390/antibiotics10080946
  61. 10.1038/s41467-022-33294-w · DOI · Paper page
  62. 10.1111/jam.15647 · DOI
  63. 10.1371/journal.pone.0168615 · DOI · Paper page
  64. 10.1128/spectrum.04636-22 · DOI
  65. 10.1016/j.micpath.2019.01.032 · DOI
  66. 10.1016/j.bpc.2020.106456 · DOI
  67. 10.1100/2012/402919 · DOI
  68. 10.1186/s12941-020-00389-5 · DOI · Paper page
  69. 10.3389/fmicb.2020.00327 · DOI · Paper page
  70. 10.1016/j.jmb.2022.167670 · doi:10.1016/j.jmb.2022.167670
  71. 10.1016/j.envres.2023.116586 · doi:10.1016/j.envres.2023.116586
  72. 10.1128/mBio.01462-20 · DOI · Paper page
  73. 10.1038/nrmicro.2017.61 · DOI · Paper page
  74. 10.1128/AEM.00757-12 · DOI · Paper page
  75. 10.3389/fmicb.2021.613529 · DOI
  76. 10.3389/fcimb.2017.00418 · DOI · Paper page
  77. 10.2217/fmb.13.47 · DOI · Paper page
  78. 10.1101/2023.01.23.22283996 · doi:10.1101/2023.01.23.22283996
  79. 10.1111/j.1462-2920.2009.02030.x · DOI
  80. 10.1128/JB.01441-07 · doi:10.1128/jb.01441-07
  81. 10.1080/1040841X.2016.1208146 · DOI · Paper page
  82. 10.1007/s10096-023-04638-1 · DOI
  83. 10.1007/978-1-60327-164-6_2 · DOI · Paper page
  84. 10.1007/978-1-60327-164-6_14 · DOI · Paper page
  85. 10.3389/fmicb.2020.594868 · DOI
  86. 10.1186/s12859-023-05341-w · DOI
  87. 10.1101/2023.02.24.529883 · doi:10.1101/2023.02.24.529883
  88. 10.1016/j.jmb.2017.12.007 · DOI · Paper page
  89. 10.1128/AAC.02149-21 · DOI
  90. 10.1128/spectrum.04671-22 · doi:10.1128/spectrum.04671-22

Cited by

See all 36

Metadata

Authors
De Soir, S., Parée, H., Kamarudin, N. H. N., Wagemans, J., Lavigne, R., Braem, A., Merabishvili, M., De Vos, D., Pirnay, J.-P., & Van Bambeke, F.
Affiliations
  • Pharmacologie cellulaire et moléculaire, Louvain Drug Research Institute, Université catholique de Louvain , Brussels, Belgium
  • Department of Materials Engineering, Biomaterials and Tissue Engineering Research Group, KU Leuven , Leuven, Belgium
  • Laboratory of Gene Technology, KU Leuven , Leuven, Belgium
  • Laboratory for Molecular and Cellular Technology (LabMCT), Queen Astrid Military Hospital , Neder-over-Heembeek, Belgium
Venue
Microbiology Spectrum
Published
2024-01-11
Volume
12
Issue
1
ISSN
2165-0497
Cited by
36
References
2
Language
en
Licence
Funders
  • Innoviris (2019-PHD-9)
  • Fonds De La Recherche Scientifique - FNRS (J.0177.23, J.0162.19)
  • Fonds Wetenschappelijk Onderzoek (W000921N)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Exploiting phage-antibiotic synergies to disrupt Pseudomonas aeruginosa PAO1 biofilms in the context of orthopedic infections. https://app.cochat.ai/papers/10.1128/spectrum.03219-23
The paper
De Soir, S., Parée, H., Kamarudin, N. H. N., Wagemans, J., Lavigne, R., Braem, A., Merabishvili, M., De Vos, D., Pirnay, J.-P., & Van Bambeke, F. (2024). Exploiting phage-antibiotic synergies to disrupt Pseudomonas aeruginosa PAO1 biofilms in the context of orthopedic infections. Microbiology Spectrum. https://doi.org/10.1128/spectrum.03219-23

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.